Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy
17. September 2014 14:52 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
Prosensa announces 12 presentations at the 19th International Congress of the World Muscle Society in Berlin
09. September 2014 09:00 ET
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
08. September 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
Prosensa to Present at Upcoming Conferences
03. September 2014 08:51 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced
presentations at upcoming investor conferences. Celia Economides,
Senior Director,...
Prosensa Announces 2nd Quarter 2014 Financial Results and Recent Corporate Developments
12. August 2014 07:00 ET
|
Prosensa Holding N.V.
NDA submission for drisapersen in Q4 2014 on track
EMA filing for conditional approval following NDA Submission
Drisapersen re-dosing on track prior to the end of September
Cash &...
Prosensa and CureDuchenne Strengthen Long-term Collaboration with an Additional [Eur]5M to Advance DMD Pipeline
11. August 2014 16:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
Prosensa to Present at the Wedbush 2014 Life Sciences Conference
06. August 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
Schikan, Chief Executive Officer, will present a corporate overview
at the...
Prosensa Holding N.V. to Webcast Conference Call Discussing 2nd Quarter 2014 Financial Results and Corporate Update on August 12, 2014
04. August 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today
announced that the Company will host a conference call and live
audio webcast on Tuesday,...
Prosensa Announces Extraordinary Shareholder Meeting to Appoint Dr. Annalisa Jenkins
14. Juli 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, July 14, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...
Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million
07. Juli 2014 13:58 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, July 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...